Welcome to CSNpharm! For Research Use Only!
c-Met/HGFR
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN28428 | XL092 | 2367004-54-2 | XL-092 is an ATP-competitive inhibitor of multiple receptor tyrosine kinases including MET, VEGFR2, AXL and MER, with IC50 values of 15, 1.6, 3.4, and 7.2 nM, respectively, in cell-based assays. |
| CSN28428 | XL092 | 2367004-54-2 | XL-092 is an ATP-competitive inhibitor of multiple receptor tyrosine kinases including MET, VEGFR2, AXL and MER, with IC50 values of 15, 1.6, 3.4, and 7.2 nM, respectively, in cell-based assays. |
| CSN17399 | Tyrosine kinase inhibitor | 1021950-26-4 | Tyrosine kinase inhibitor is a drug used for advanced renal cell carcinoma |
| CSN16106 | SGX-523 | 1022150-57-7 | SGX-523 is a potent and selective c-Met inhibitor with IC50 of 4 nM |
| CSN17517 | SCR-1481B1 | 1174161-86-4 | SCR-1481B1 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor |
| CSN17684 | Savolitinib | 1313725-88-0 | Savolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase (IC50 5 nM) with potential antineoplastic activity. |
| CSN20348 | SAR125844 | 1116743-46-4 | SAR125844 is a potent and highly selective c-Met inhibitor with potential antineoplastic activity |
| CSN19153 | S49076 | 1265965-22-7 | S49076 is a potent inhibitor of MET AXLMER and FGFRs |
| CSN22605 | S49076 HCl | 1265966-31-1 | S49076 hydrochloride is a potent, ATP-competitive tyrosine kinase inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 <20 nM. |
| CSN26511 | PF-04217903 phenolsulfonate | 1159490-85-3 | PF-04217903 phenolsulfonate is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 phenolsulfonate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties[1][2]. |
| CSN18635 | PF-04217903 methanesulfonate | 956906-93-7 | PF-04217903 Methanesulfonate is a highlu selective c-Met inhibitor with IC50 of 48 nM |
| CSN16129 | PF-04217903 | 956905-27-4 | PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 48 nM susceptible to oncogenic mutations no activity to Y1230C mutant |
| CSN17159 | NVP-BVU972 | 1185763-69-2 | NVP-BVU972 is a potent and selective c-Met inhibitor with IC50 of 14 nM with antitumor effects |
| CSN23572 | Norcantharidin | 29745-04-8 | Norcantharidin is a potential antitumor agent. |
| CSN23685 | Ningetinib Tosylate | 1394820-77-9 | Ningetinib tosylate is an inhibitor of tyrosine kinase inhibitor TKI and the IC50 for c-Met VEGFR2 and Axl are 67 nM 19 nM and 10 nM respectively |
| CSN24062 | Ningetinib | 1394820-69-9 | Ningetinib is an inhibitor of tyrosine kinase inhibitor (TKI) and the IC50 for c-Met, VEGFR2 and Axl are 6.7 nM, 1.9 nM and <1.0 nM respectively. |
| CSN17658 | MK-8033 hydrochloride | 1283000-43-0 | MK8033 HCl is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer. |
| CSN13613 | MK-8033 | 1001917-37-8 | MK-8033 is a specific dual ATP competitive c-MetRon inhibitor IC501 nM Wt c-Met under investigation as a treatment for cancer |
| CSN16566 | MK-2461 | 917879-39-1 | MK-2461 is a potent and multi-targeted inhibitor for c-Met with IC50 of 04-25 nM also inhibits FGFR123 KDR TrkAB and Flt4 with IC50 of 653950 nM 44 nM 4661 nM and 78 nM respectively |
| CSN26620 | MET kinase-IN-2 | 2101241-90-9 | MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM. MET kinase-IN-2 has antitumor activity[1]. |
| CSN13734 | Merestinib | 1206799-15-6 | LY2801653 is a potent and orally bioavailable inhibitor of c-MET kinase with Ki of 2 nM |
| CSN17560 | Merestinib dihydrochloride | 1206801-37-7 | LY2801653 2HCl is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase (Ki= 2 nM). |
| CSN22436 | JNJ-38877618 | 943540-74-7 | JNJ-38877618 is a potent highly selective orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met respectively |
| CSN12936 | JNJ-38877605 | 943540-75-8 | JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM |
| CSN15776 | Capmatinib | 1029712-80-8 | INCB28060 is a potent and selective c-MET kinase inhibitor. INCB28060 inhibits c-MET kinase activity with an average IC50 of 0.13 nM. |
| CSN19988 | Herbacetin | 527-95-7 | Herbacetin, a natural product isolated and purified from the herbs of Equisetum hyemale L. It was found to efficiently block the enzymatic activity of SARS-CoV 3CLpro. |
| CSN15829 | Golvatinib | 928037-13-2 | Golvatinib is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM |
| CSN24153 | Glumetinib | 1642581-63-2 | Glumetinib is a novel, potent and highly selective inhibitor of c-Met. |
| CSN17479 | Glesatinib hydrochloride | 1123838-51-6 | Glesatinib HCl is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered. |
| CSN12685 | Foretinib | 849217-64-7 | Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Foretinib is less potent against Ron, Flt-134, Kit, PDGFR and Tie-2, and with little activity to FGFR1 and EGFR. |
| CSN22549 | Ensartinib | 1370651-20-9 | Ensartinib is a novel potent anaplastic lymphoma kinase ALK small molecule tyrosine kinase inhibitor TKI with additional activity against MET ABL Axl EPHA2 LTK ROS1 and SLK ALK autophosphorylation is significantly diminished by X-396 albeit at higher concentrations required to block autophosphorylation of the wild-type fusion |
| CSN26544 | EGFR-IN-8 | 2407957-87-1 | EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC[1]. |
| CSN24316 | N-((S)-1-(((2S,3S)-1-((6-Amino-6-oxohexyl)amino)-3-methyl-1-oxopentan-2-yl)amino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)hexanamide acetate | 2453297-24-8 | Dihexa is a blood-brain barrier-permeable angiotensin IV analog which exhibits high affinity to HGF with Kd value of 65pM and induces c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering. |
| CSN24802 | BPR1K871 | 2443767-35-7 | DBPR114 is a potent multi-kinase inhibitor with potent activities against more than 57 oncogenic kinases, including Aurora-A, FLT3, CSF1R, MET, etc. DBPR114 exhibited favorable PK profiles: a long half-life (t1/2 = 23.5 h), moderate clearance and high volume of distribution. Also DBPR114 can effectively inhibit the growth of human acute myeloid leukemia MOLM-13 and MV4-11, MIA PaCa-2, Hep3B, MKN45, Colo205, and NTUB1 solid tumor xenografts in vivo without causing significant body weight loss. |
| CSN15710 | Cabozantinib | 849217-68-1 | Cabozantinib is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-134, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM11.3 nM6 nM, 14.3 nM and 7 nM, respectively. |
| CSN25585 | SYN1143 | 913376-84-8 | c-Met/RON Dual Kinase Inhibitor is a potent inhibitor against the kinase activities of HGF receptor c-Met and MSP (Macrophage Stimulating Protein) receptor RON with IC50 of 4 and 9 nM, respectively, and it is reported to inhibit NIH3T3 TRP-Met and U-87 tumor growth in mice in vivo in a dose-dependent manner. |
| CSN22378 | c-Met-IN-2 | 1635406-73-3 | c-Met-IN-2 is a potent selective and orally available c-Met inhibitor with an IC50 of 06 nM with antitumor activity |
| CSN16262 | c-Met inhibitor 1 | 1357072-61-7 | c-Met Inhibitor 1 is a c-Met receptor signaling pathway inhibitor used for the treatment of cancer including gastric glioblastoma and pancreatic cancer |
| CSN23729 | Bozitinib | 1440964-89-5 | Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1]. |
| CSN16525 | BMS-794833 | 1174046-72-0 | BMS-794833 is a potent ATP competitive inhibitor of Met and VEGFR2 with IC50 of 17 and 15 nM |
| CSN13471 | BMS 777607 | 1025720-94-8 | BMS-777607 is a Met-related inhibitor for c-Met Axl Ron and Tyro3 with IC50 of 39 nM 11 nM 18 nM and 43 nM being 40-fold selective for Met-related targets versus Lck VEGFR-2 and TrkAB and more than 500-fold greater selectivity versus all other receptor and non receptor kinases |
| CSN15865 | BMS-754807 | 1001350-96-4 | BMS-754807 is a potent and reversible inhibitor of IGF-1RInsR with IC50 of 18 nM17 nM less potent to Met Aurora AB TrkAB and Ron and shows little activity to Flt3 Lck MK2 PKA PKC etc |
| CSN25296 | BAY-474 | 1033767-86-0 | BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe. |
| CSN17199 | AMG-458 | 913376-83-7 | AMG-458 is a potent c-Met inhibitor with Ki of 12 nM 350-fold selectivity for c-Met than VEGFR2 in cells |
| CSN17516 | AMG-337 | 1173699-31-4 | AMG-337 is a potent highly selective and ATP-competitive MET kinase inhibitor with an IC50 of 5nM in enzymatic assays |
| CSN16548 | AMG-208 | 1002304-34-8 | AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 93 nM |
| CSN16259 | Altiratinib | 1345847-93-9 | Altiratinib is a c-METTIE-2VEGFR inhibitor which effectively reduce tumor burden in vivo and block c-MET pTyr1349-mediated signaling cell growth and migration as compared with a HGF antagonist in vitro |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
